A real-world study found both vandetanib and cabozantinib to be effective in treating patients with advanced MTC.
Researchers found that artificial light at night may disrupt circadian rhythm, leading to an increased risk of developing thyroid cancer.
Researchers have found a significant increase in the OS of patients with ATC patients from 2000 to 2019, suggesting that advances in treatment have improved survival.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
Study findings suggest there may be an association between advancing age and reduced risk for papillary thyroid tumor enlargement being actively monitored.
The FDA has approved selpercatinib for the treatment of patients with NSCLC, MTC, and other thyroid cancers with tumors harboring a RET alteration.
Researchers stress the importance of tailoring therapies for disproportionately increasing subtypes of aggressive papillary thyroid carcinomas.
Stay in the know.
OncNet Newsletter